The data shows that immune cells converge at sites of motor neuron loss and TDP-43 pathology with distinct patterns depending on the ALS type.
The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...
The CEO of Caszyme, a biotech company in Vilnius, Lithuania, presented details of Cas12l, a novel compact Cas nuclease with a ...
The new CRISPR platform, called ΨDNA, reprograms Cas12 nucleases to recognize and act on RNA using a DNA-based guide scaffold ...
When these anchors are attached to cancer drugs, they attach to cell membranes and shrink tumors better than unmodified drug ...
These “living therapeutics” can sustain themselves in vivo and survive in biological environments including tumors, inflamed ...
Bristol Myers Squibb (BMS) will partner with Hengrui Pharma to co-develop 13 early-stage programs in oncology, hematology, ...
One of the winners of the 2026 ASGCT Catalyst Award, Kiran Musunuru, MD, PhD, delivered a sobering lecture on the legacy of ...
Sickle cell warrior Victoria Gray, the first patient to enroll in the Casgevy gene editing trial, shared some highs and lows ...
New POLARIS Phase I/II data presented at ASGCT show ETX101 gene therapy reducing seizures and improving neurodevelopment in ...
ADC manufacturing demands stronger operator protection as potent compounds raise containment and safety challenges.
Light may damage antibody drug conjugates during manufacturing; however, novel chemistries help simplify downstream processes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results